默沙东百亿美元收购打开BD新风口,中国药企机会来了

医药魔方
Jul 12, 2025

在制药巨头的并购版图中,“大鱼吃小鱼”从来不是简单的资本游戏,而是对未来市场格局的精准布局。默沙东在并购方面向来活跃。据医药魔方NextPharma数据库统计,默沙东历年并购交易数量在跨国药企中排名第二。不过相比动辄数百亿美元的大型吞并交易,默沙东更热衷于中小规模的并购,尤其偏好单个项目价值高的生物技术公司,Acceleron Pharma、Prometheus Biosciences、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10